NKGN,NKGen Biotech, Inc. | Healthcare

Healthcare

NKGN

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

NKGen Biotech, Inc.NKGN

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies.

It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.

The company was founded in 2017 and is based in Santa Ana, California.

Latest News >

Aircraft lessor Avolon books $177 million from Russian insurance settlement

Feb 13, 2025

DUBLIN, Feb 13 (Reuters) - Aircraft lessor Avolon has booked $177 million in proceeds from settlements of insurance claims in respect of aircraft stranded in Russia after Western sanctions in 2022 and does not expect additional recoveries. Avolon, the world's second -largest aircraft lessor, last week said it had discontinued court proceedings in Ireland after reaching commercial resolutions with its...

Toronto-Dominion Bank Completes Sale of Stake in Charles Schwab

Feb 13, 2025

03:44 AM EST, 02/13/2025 (MT Newswires) -- Toronto-Dominion Bank ( MLWIQXX ) said late Wednesday it completed the sale of its entire equity investment in Charles Schwab ( SCHW ) , which consisted of about 184.7 million shares representing a 10.1% stake. The company said it sold about 165.4 million shares through a registered offering at $79.25 per share, while...

Travere Therapeutics Insider Sold Shares Worth $1,356,100, According to a Recent SEC Filing

Feb 13, 2025

03:44 AM EST, 02/13/2025 (MT Newswires) -- Sandra Calvin, Senior Vice President and Chief Accounting Officer, on February 11, 2025, sold 54,244 shares in Travere Therapeutics ( TVTX ) for $1,356,100. Following the Form 4 filing with the SEC, Calvin has control over a total of 54,410 common shares of the company, with 54,410 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1438533/000141588925003822/xslF345X05/form4-02132025_020258.xml...

Roblox Insider Sold Shares Worth $1,724,673, According to a Recent SEC Filing

Feb 13, 2025

03:42 AM EST, 02/13/2025 (MT Newswires) -- Michael Guthrie, Chief Financial Officer, on February 10, 2025, sold 26,154 shares in Roblox ( RBLX ) for $1,724,673. Following the Form 4 filing with the SEC, Guthrie has control over a total of 478,501 Class A common shares of the company, with 417,079 shares held directly and 61,422 controlled indirectly. SEC Filing:...